Source: centralcharts

Press Release: Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming

Read full article »

Exscientia's Competitors | Exscientia's News | Exscientia's Financials

Followers on Owler

Annual Revenue

$25-100M

Employees

250-500

Interim-CEO

Dave Hallett

CEO Approval Rating

87/100

Exscientia is an England-based biotech company that develops an AI-driven platform offering solutions such as drug discovery and development for the pharmaceutical industry.